United States Biotechnology & Medical Research

Cymabay Therapeutics Inc (CBAY)

Track

Ticker: CBAY Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Cymabay Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 15 Feb 2024
Value US$3,623,779.42 | Price 366.54 | Shares 31,786
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-02-15 2024-02-15 PrS Proposed sale
DANIEL MENOLD

Officer

Officer
31,786
366.54
US$3,623,779 		31,786 366.54 US$3,623,779
2024-02-14 2024-02-12 PlS Planned sale
Dorling Janet
Non-Executive Director
27,073 +49.5%
489.25
US$4,284,104 		27,073 +49.5% 489.25 US$4,284,104
2024-02-12 2024-02-12 PrS Proposed sale
JANET DORLING

Director

Non-Executive Director
50,239
311.93
US$2,388,920 		50,239 311.93 US$2,388,920
2024-02-06 2024-02-06 PrS Proposed sale
STUART LEWIS J

Officer

Officer
30,620
23.95
US$733,349 		30,620 23.95 US$733,349
2024-02-01 2024-02-01 PrS Proposed sale
Menold Daniel

Officer

Officer
25,000
24.00
US$600,000 		25,000 24.00 US$600,000
2024-01-30 2024-01-30 PrS Proposed sale
Menold Daniel

Officer

Officer
25,000
23.75
US$593,750 		25,000 23.75 US$593,750
2024-01-29 2024-01-29 PrS Proposed sale
Menold Daniel

Officer

Officer
50,000
23.92
US$1,195,750 		50,000 23.92 US$1,195,750
2024-01-26 2024-01-26 PrS Proposed sale
Menold Daniel

Officer

Officer
20,000
23.04
US$460,806 		20,000 23.04 US$460,806
2024-01-22 2024-01-22 PrS Proposed sale
STUART LEWIS J

Officer

Officer
62,257
24.50
US$1,525,296 		62,257 24.50 US$1,525,296
2024-01-22 2024-01-19 PlS Planned sale
2.7
McWherter Charles

President of R&D

Officer
3,125 -17.2%
23.68
US$73,988 		3,125 -17.2% 23.68 US$73,988
2024-01-22 2024-01-19 PlS Planned sale
2.7
McWherter Charles

President of R&D

Officer
8,334 -35.7%
23.68
US$197,316 		8,334 -35.7% 23.68 US$197,316
2024-01-22 2024-01-19 PlS Planned sale
2.7
McWherter Charles

President of R&D

Officer
1,916 -11.3%
23.66
US$45,340 		1,916 -11.3% 23.66 US$45,340
2024-01-22 2024-01-19 PlS Planned sale
2.7
McWherter Charles

President of R&D

Officer
2,778 -15.6%
23.66
US$65,739 		2,778 -15.6% 23.66 US$65,739
2024-01-22 2024-01-19 PlS Planned sale
2.7
McWherter Charles

President of R&D

Officer
2,250 -13.0%
23.67
US$53,262 		2,250 -13.0% 23.67 US$53,262
2024-01-19 2024-01-19 PrS Proposed sale
STUART LEWIS J

Officer

Officer
50,000
23.40
US$1,170,000 		50,000 23.40 US$1,170,000
2024-01-19 2024-01-19 PrS Proposed sale
2.7
CHARLES MCWHERTER

Officer

Officer
18,403
23.67
US$435,645 		18,403 23.67 US$435,645
2024-01-18 2024-01-18 PrS Proposed sale
STUART LEWIS J

Officer

Officer
60,749
23.40
US$1,421,527 		60,749 23.40 US$1,421,527
2024-01-17 2024-01-17 PrS Proposed sale
STUART LEWIS J

Officer

Officer
40,158
23.40
US$939,697 		40,158 23.40 US$939,697
2024-01-16 2024-01-16 PrS Proposed sale
0.6
PAUL QUINLAN

Officer

Officer
5,000
23.58
US$117,898 		5,000 23.58 US$117,898
2024-01-16 2024-01-16 PrS Proposed sale
DANIEL MENOLD

Officer

Officer
10,000
23.58
US$235,806 		10,000 23.58 US$235,806
2024-01-16 2024-01-16 PlS Planned sale
0.6
Quinlan Paul T

General Counsel

Officer
5,000 -100.0%
23.58
US$117,898 		5,000 -100.0% 23.58 US$117,898
2024-01-16 2024-01-16 PlS Planned sale
Menold Daniel

Vice President, Finance

Officer
10,000 -100.0%
23.58
US$235,806 		10,000 -100.0% 23.58 US$235,806
2024-01-10 2024-01-10 PrS Proposed sale
JANET DORLING

Director

Non-Executive Director
6,000
23.86
US$143,144 		6,000 23.86 US$143,144
2024-01-10 2024-01-10 PlS Planned sale
Dorling Janet
Non-Executive Director
6,000 -100.0%
23.86
US$143,144 		6,000 -100.0% 23.86 US$143,144
2024-01-03 2024-01-03 PrS Proposed sale
STUART LEWIS J

Officer

Officer
337,583
24.25
US$8,186,388 		337,583 24.25 US$8,186,388
2023-12-18 2023-12-18 PrS Proposed sale
2.7
CHARLES MCWHERTER

Officer

Officer
11,332
21.48
US$243,440 		11,332 21.48 US$243,440
2023-12-18 2023-12-18 PlS Planned sale
2.7
McWherter Charles

President of R&D

Officer
6,504 -30.2%
21.48
US$139,703 		6,504 -30.2% 21.48 US$139,703
2023-12-18 2023-12-18 PlS Planned sale
2.7
McWherter Charles

President of R&D

Officer
4,828 -24.3%
21.49
US$103,738 		4,828 -24.3% 21.49 US$103,738
2023-12-15 2023-12-15 PrS Proposed sale
0.6
PAUL QUINLAN

Officer

Officer
5,000
21.98
US$109,902 		5,000 21.98 US$109,902
2023-12-15 2023-12-15 PrS Proposed sale
DANIEL MENOLD

Officer

Officer
21,497
21.99
US$472,646 		21,497 21.99 US$472,646
2023-12-15 2023-12-15 PlS Planned sale
Menold Daniel

Vice President, Finance

Officer
11,497 -100.0%
21.99
US$252,799 		11,497 -100.0% 21.99 US$252,799
2023-12-15 2023-12-15 PlS Planned sale
Menold Daniel

Vice President, Finance

Officer
10,000 -100.0%
21.98
US$219,847 		10,000 -100.0% 21.98 US$219,847
2023-12-15 2023-12-15 PlS Planned sale
0.6
Quinlan Paul T

General Counsel

Officer
5,000 -100.0%
21.98
US$109,902 		5,000 -100.0% 21.98 US$109,902
2023-12-11 2023-12-11 PrS Proposed sale
3.6
SUJAL A SHAH

Officer; Director

Executive Director
64,865
20.00
US$1,297,164 		64,865 20.00 US$1,297,164
2023-12-11 2023-12-11 PrS Proposed sale
JANET DORLING

Director

Non-Executive Director
6,000
20.07
US$120,422 		6,000 20.07 US$120,422
2023-12-11 2023-12-11 PlS Planned sale
Dorling Janet
Non-Executive Director
6,000 -100.0%
20.07
US$120,422 		6,000 -100.0% 20.07 US$120,422
2023-12-11 2023-12-11 PlS Planned sale
3.6
Shah Sujal

Chief Executive Officer

Executive Director
890 -0.5%
20.81
US$18,521 		890 -0.5% 20.81 US$18,521
2023-12-11 2023-12-11 PlS Planned sale
3.6
Shah Sujal

Chief Executive Officer

Executive Director
63,975 -27.2%
19.99
US$1,278,649 		63,975 -27.2% 19.99 US$1,278,649
2023-11-17 2023-11-17 PrS Proposed sale
2.7
CHARLES MCWHERTER

Officer

Officer
11,342
18.28
US$207,293 		11,342 18.28 US$207,293
2023-11-17 2023-11-17 PlS Planned sale
2.7
McWherter Charles

President of R&D

Officer
11,342 -43.1%
18.28
US$207,293 		11,342 -43.1% 18.28 US$207,293
2023-11-17 2023-11-15 PlS Planned sale
0.6
Quinlan Paul T

General Counsel

Officer
5,000 -100.0%
17.38
US$86,889 		5,000 -100.0% 17.38 US$86,889
2023-11-17 2023-11-15 PlS Planned sale
Menold Daniel

Vice President, Finance

Officer
0
17.38
US$0 		0 17.38 US$0
2023-11-15 2023-11-15 PrS Proposed sale
0.6
PAUL QUINLAN

Officer

Officer
5,000
17.38
US$86,889 		5,000 17.38 US$86,889
2023-11-15 2023-11-15 PrS Proposed sale
DANIEL MENOLD

Officer

Officer
17,500
17.38
US$304,146 		17,500 17.38 US$304,146
2023-11-14 2023-11-13 PlS Planned sale
3.6
Shah Sujal

Chief Executive Officer

Executive Director
20,855 -10.9%
15.89
US$331,350 		20,855 -10.9% 15.89 US$331,350
2023-11-14 2023-11-13 PlS Planned sale
3.6
Shah Sujal

Chief Executive Officer

Executive Director
44,008 -20.4%
15.89
US$699,309 		44,008 -20.4% 15.89 US$699,309
2023-11-13 2023-11-13 PrS Proposed sale
3.6
SUJAL A SHAH

Officer; Director

Executive Director
64,863
15.89
US$1,030,655 		64,863 15.89 US$1,030,655
2023-11-14 2023-11-10 PlS Planned sale
Dorling Janet
Non-Executive Director
7,000 -100.0%
15.24
US$106,700 		7,000 -100.0% 15.24 US$106,700
2023-11-13 2023-11-10 PrS Proposed sale
JANET DORLING

Director

Non-Executive Director
7,000
15.24
US$106,700 		7,000 15.24 US$106,700
2023-10-18 2023-10-18 PrS Proposed sale
2.7
CHARLES MCWHERTER

Officer

Officer
21,743
14.07
US$305,939 		21,743 14.07 US$305,939
2023-10-18 2023-10-18 PlS Planned sale
2.7
McWherter Charles

President of R&D

Officer
21,743 -59.2%
14.07
US$305,941 		21,743 -59.2% 14.07 US$305,941
2023-10-18 2023-10-16 PlS Planned sale
Menold Daniel

Vice President, Finance

Officer
0
13.76
US$0 		0 13.76 US$0
2023-10-18 2023-10-16 PlS Planned sale
0.6
Quinlan Paul T

General Counsel

Officer
5,000 -100.0%
13.76
US$68,798 		5,000 -100.0% 13.76 US$68,798
2023-10-16 2023-10-16 PrS Proposed sale
DANIEL MENOLD

Officer

Officer
17,500
13.76
US$240,868 		17,500 13.76 US$240,868
2023-10-16 2023-10-16 PrS Proposed sale
0.6
PAUL QUINLAN

Officer

Officer
5,000
13.76
US$68,798 		5,000 13.76 US$68,798
2023-10-10 2023-10-09 PrS Proposed sale
3.6
SUJAL A SHAH

Officer; Director

Executive Director
64,861
14.20
US$921,286 		64,861 14.20 US$921,286
2023-10-10 2023-10-09 PlS Planned sale
3.6
Shah Sujal

Chief Executive Officer

Executive Director
64,861 -27.5%
14.20
US$921,286 		64,861 -27.5% 14.20 US$921,286
2023-09-29 2023-09-29 PrS Proposed sale
2.1
KONRAD HANS VON EMSTER

Director

Non-Executive Director
15,921
15.68
US$249,675 		15,921 15.68 US$249,675
2023-09-29 2023-09-29 PlS Planned sale
2.1
EMSTER KURT VON
Non-Executive Director
15,921 -15.0%
15.68
US$249,675 		15,921 -15.0% 15.68 US$249,675
2023-09-19 2023-09-18 PlS Planned sale
2.7
McWherter Charles

President of R&D

Officer
21,746 -59.2%
16.22
US$352,733 		21,746 -59.2% 16.22 US$352,733
2023-09-18 2023-09-18 PrS Proposed sale
2.7
CHARLES MCWHERTER

Officer

Officer
21,746
16.22
US$352,731 		21,746 16.22 US$352,731
2023-09-19 2023-09-15 PlS Planned sale
Menold Daniel

Vice President, Finance

Officer
0
16.87
US$0 		0 16.87 US$0
2023-09-19 2023-09-15 PlS Planned sale
Menold Daniel

Vice President, Finance

Officer
0
16.87
US$0 		0 16.87 US$0
2023-09-19 2023-09-15 PlS Planned sale
0.6
Quinlan Paul T

General Counsel

Officer
24,000 -100.0%
16.87
US$404,916 		24,000 -100.0% 16.87 US$404,916
2023-09-19 2023-09-15 PlS Planned sale
0.6
Quinlan Paul T

General Counsel

Officer
24,000 -100.0%
16.87
US$404,897 		24,000 -100.0% 16.87 US$404,897
2023-09-19 2023-09-15 PlS Planned sale
0.6
Quinlan Paul T

General Counsel

Officer
5,000 -100.0%
16.87
US$84,328 		5,000 -100.0% 16.87 US$84,328
2023-09-15 2023-09-15 PrS Proposed sale
DANIEL MENOLD

Officer

Officer
16,545
16.87
US$279,162 		16,545 16.87 US$279,162
2023-09-15 2023-09-15 PrS Proposed sale
0.6
PAUL QUINLAN

Officer

Officer
53,000
16.87
US$894,138 		53,000 16.87 US$894,138
2023-08-18 2023-08-18 PrS Proposed sale
2.7
CHARLES MCWHERTER

Officer

Officer
21,746
11.47
US$249,359 		21,746 11.47 US$249,359
2023-08-18 2023-08-18 PlS Planned sale
2.7
McWherter Charles

President of R&D

Officer
21,746 -59.2%
11.47
US$249,359 		21,746 -59.2% 11.47 US$249,359
2023-08-16 2023-08-15 PlS Planned sale
0.6
Quinlan Paul T

General Counsel

Officer
5,000 -100.0%
11.91
US$59,550 		5,000 -100.0% 11.91 US$59,550
2023-08-16 2023-08-15 PlS Planned sale
Menold Daniel

Vice President, Finance

Officer
0
12.13
US$0 		0 12.13 US$0
2023-08-16 2023-08-15 PlS Planned sale
Menold Daniel

Vice President, Finance

Officer
0
11.92
US$0 		0 11.92 US$0
2023-08-15 2023-08-15 PrS Proposed sale
0.6
PAUL QUINLAN

Officer

Officer
5,000
11.91
US$59,550 		5,000 11.91 US$59,550
2023-08-15 2023-08-15 PrS Proposed sale
DANIEL MENOLD

Officer

Officer
15,500
12.01
US$186,188 		15,500 12.01 US$186,188
Explore more

More insider trading research around Cymabay Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America